
Arsenic trioxide enhances the chemotherapeutic efficiency of cisplatin in cholangiocarcinoma cells via inhibiting the 14-3-3ε-mediated survival mechanism
Elijah
- 0
Cholangiocarcinoma (CCA) is the second most frequent main liver carcinoma with excessive levels of malignancy and mortality. Chemotherapy performs a key position within the remedy of CCA, nonetheless, the low chemotherapeutic effectivity results in a bottleneck.
So unraveling the potential mechanisms to reinforce the effectivity (lowered the dosage and enhanced the consequences of chemotherapy medicine) and figuring out different therapeutic methods in CCA are urgently wanted.
Right here, we discovered that, in CCA cells, when cisplatin (CDDP) displayed anti-tumor results, it activated 14-3-3ε concurrently, which in flip fashioned a survival mechanism through the phosphorylation of phosphatidylinositol 3-kinase/protein kinase B (PI-3K/Akt). Nonetheless, low concentrations of arsenic trioxide (ATO) might disrupt such survival mechanism and enhanced the effectivity.
For the molecular mechanisms, ATO attenuated 14-3-3ε at each transcriptional and post-transcriptional (ubiquitination degradation) ranges. Such repressive impact blocked the activation of PI-3K/Akt, and its downstream anti-apoptotic elements, B-cell lymphoma 2 (Bcl-2), and survivin. Collectively, our current research revealed that the synergistic results of ATO and CDDP could possibly be a novel strategy for enhancing the effectivity, which supplies an revolutionary therapeutic imaginative and prescient for the remedy of CCA.
Lengthy-Time period High quality of Lifetime of Acute Promyelocytic Leukemia Sufferers Handled with Arsenic Trioxide versus Chemotherapy
The principle goal of this research was to check the long-term health-related high quality of lifetime of sufferers with acute promyelocytic leukemia (APL) handled with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) versus ATRA plus customary chemotherapy.
Sufferers beforehand enrolled within the randomized managed trial APL0406 have been thought-about eligible for this follow-up research. The next patient-reported end result measures have been used: the EORTC QLQ-C30, the EORTC QLQ-CIPN20 and the SF-36. The prevalence of late comorbidities and well being issues was additionally assessed.
The scientific significance of variations was evaluated primarily based on predefined thresholds. This research was registered. 100 sixty-one out of 232 doubtlessly eligible sufferers have been analyzed, of whom 83 have been handled with ATRA-ATO and 78 have been handled with ATRA-chemotherapy. The median time since prognosis of the research pattern was Eight years.
The 2 largest clinically significant variations within the EORTC QLQ-C30 have been noticed for position functioning (Δ=8.4, 95% CI, 0.5 to 16.3) and dyspnea (Δ=-8.5, 95% CI, -16.Four to -0.7), favoring sufferers handled with ATRA-ATO.
With regard to the SF-36 outcomes, a clinically related higher bodily element rating (Δ=4.6, 95% CI, 1.Three to 7.8) was noticed in sufferers handled with ATRA-ATO, however this was not the case for the psychological element rating. The 2 teams confirmed comparable profiles within the scores of the EORTC QLQ-CIPN20 scales and within the prevalence of late comorbidities.
General, our findings counsel that the larger and extra sustained antileukemic efficacy of ATRA-ATO can also be related to higher long-term patient-reported outcomes than ATRA-chemotherapy.
New Bioactive Calcium Silicate Cement Mineral Trioxide Combination Restore Excessive Plasticity (MTA HP)-A Systematic Assessment
Bioactive calcium silicate cement Mineral Trioxide Combination (MTA) has been used for years as a gold customary in intravital pulp remedy and specialist endodontic procedures.
Owing to flaws of the fabric, the producers have been making an attempt to reinforce and produce supplies displaying improved bodily, chemical and organic parameters. One of many new calcium-silicate cements primarily based on mineral trioxide mixture, nonetheless with out some flaws exhibited by the cement, is Mineral Trioxide Combination Restore Excessive Plasticity (MTA HP).
The intention of the current paper was a scientific literature assessment regarding the MTA HP materials used these days in dentistry, as a assessment of its particular options. The current paper is the primary article offering a scientific literature assessment on MTA HP.
The intention of the current article is the higher understanding of MTA HP properties, which may support the decision-making course of in endodontic remedy.

Genetic Expression Screening of Arsenic Trioxide-Induced Cytotoxicity in KG-1a Cells Based mostly on Bioinformatics Expertise
Acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system, and leukemia stem cells are chargeable for AML chemoresistance and relapse. KG-1a cell is taken into account a leukemia stem cell-enriched cell line, which is immune to chemotherapy.
Arsenic trioxide (ATO) is efficient in opposition to acute promyelocytic leukemia as a first-line remedy agent, at the same time as remission induction of relapsed instances. ATO has a cytotoxic impact on KG-1a cells, however the mechanism stays unclear. Our outcomes demonstrated that ATO can inhibit cell proliferation, induce apoptosis, and arrest KG-1a cells within the G2/M part.
Utilizing transcriptome evaluation, we investigated the candidate goal genes regulated by ATO in KG-1a cells. The expression profile evaluation confirmed that the ATO had considerably modified gene expression associated to proliferation, apoptosis, and cell cycle. Furthermore, MYC, PCNA, and MCM7 have been recognized as essential hub genes by means of protein-protein interplay community evaluation; in the meantime, the expressions of them in each RNA and protein ranges are down-regulated as confirmed by quantitative polymerase chain response and Western blot.
Thus, our research means that ATO not solely inhibits the expression of MYC, PCNA, and MCM7 but additionally results in cell cycle arrest and apoptosis in KG-1a cells. General, this research offered dependable clues for bettering the ATO efficacy in AML
Ultrasonically assisted conversion of uranium trioxide into uranium(VI) intrinsic colloids
Beneath oxidizing situations, the corrosion of spent nuclear gasoline might result in the leaching of radionuclides together with soluble uranyl-based species. The speciation of the generated chemical varieties is complicated and the associated potential formation of colloidal species seems surprisingly poorly reported within the literature.
Their formation might nonetheless contribute considerably to the mobility of radionuclides within the surroundings. A greater data within the speciation and reactivity of those species seems notably related. This research describes the preparation and characterization of intrinsic uranium(vi) colloids from amorphous and crystalline UO3 in pure water assisted by 20 kHz ultrasound.
Within the presence of carbon monoxide stopping the sonochemical formation of hydrogen peroxide, ultrasonic remedy boosts the conversion of UO3 powder into (meta-)schoepite precipitates and yields very secure and notably concentrated uranium(vi) nanoparticles within the liquid part. Utilizing HR-TEM, SAXS and XAS strategies, we confirmed that the colloidal suspension consists of quasi-spherical nanoparticles measuring ca. 3.8 ± 0.Three nm and exhibiting a schoepite-like crystallographic construction.
Antimony Ingot, 99.9999% |
|||
GX7081-50 | Glentham Life Sciences | 50 | EUR 249.2 |
Antimony Ingot, 99.999% |
|||
GX8708-100 | Glentham Life Sciences | 100 | EUR 277.1 |
Antimony Ingot, 99.999% |
|||
GX8708-500 | Glentham Life Sciences | 500 | EUR 728.4 |
Antimony Pieces, 99.999% |
|||
GX7845-100 | Glentham Life Sciences | 100 | EUR 340.5 |
Antimony Pieces, 99.999% |
|||
GX7845-25 | Glentham Life Sciences | 25 | EUR 134.1 |
Antimony Pieces, 99.999% |
|||
GX7845-500 | Glentham Life Sciences | 500 | EUR 1218.8 |
Antimony Pieces, 99.9999% |
|||
GX8733-25 | Glentham Life Sciences | 25 | EUR 180.9 |
Antimony Pieces, 99.9999% |
|||
GX8733-250 | Glentham Life Sciences | 250 | EUR 751 |
Antimony Pieces, 99.9999% |
|||
GX8733-50 | Glentham Life Sciences | 50 | EUR 283.5 |
Antimony(III) sulfide |
|||
GX5942-500 | Glentham Life Sciences | 500 | EUR 164.8 |
Antimony(V) chloride |
|||
GX8478-250 | Glentham Life Sciences | 250 | EUR 200.6 |
Antimony potassium tartrate trihydrate |
|||
A100-2x25G | TOKU-E | 2 x 25 g | EUR 75.6 |
Antimony potassium tartrate trihydrate |
|||
A100-4x25G | TOKU-E | 4 x 25 g | EUR 100.8 |
Antimony(V) pentasulfide |
|||
GX8145-50G | Glentham Life Sciences | 50 g | EUR 211.2 |
Antimony(V) pentasulfide |
|||
GX8145-50 | Glentham Life Sciences | 50 | EUR 145.1 |
Antimony(III) oxide, 98+% |
|||
GX8352-500 | Glentham Life Sciences | 500 | EUR 128.1 |
Antimony(III) oxide, 99.99+% |
|||
GX8841-100 | Glentham Life Sciences | 100 | EUR 358.4 |
Antimony(III) oxide, 99.99+% |
|||
GX8841-25 | Glentham Life Sciences | 25 | EUR 169.5 |
Antimony(III) oxide, 99.9% |
|||
GX1943-250 | Glentham Life Sciences | 250 | EUR 685.9 |
Antimony(III) oxide, 99.9% |
|||
GX1943-50 | Glentham Life Sciences | 50 | EUR 228.1 |
Antimony tin oxide, 99.95 % |
|||
GX2870-1 | Glentham Life Sciences | 1 | EUR 1079.3 |
Antimony tin oxide, 99.95 % |
|||
GX2870-100 | Glentham Life Sciences | 100 | EUR 221.7 |
Antimony tin oxide, 99.95 % |
|||
GX2870-25 | Glentham Life Sciences | 25 | EUR 129.6 |
Antimony tin oxide, 99.95 % |
|||
GX2870-250 | Glentham Life Sciences | 250 | EUR 416.4 |
Antimony(III) iodide, 99.999% |
|||
GX5562-10 | Glentham Life Sciences | 10 | EUR 683.6 |
Antimony(III) fluoride, 99% |
|||
GX8250-250 | Glentham Life Sciences | 250 | EUR 129.6 |
Antimony(III) chloride, 99.99+% |
|||
GX1593-10 | Glentham Life Sciences | 10 | EUR 119.1 |
Antimony(III) chloride, 99.99+% |
|||
GX1593-50 | Glentham Life Sciences | 50 | EUR 407.4 |
Antimony(III) chloride, 99% |
|||
GX2593-250 | Glentham Life Sciences | 250 | EUR 129.6 |
Antimony tin oxide (ATO); 99,95 % |
|||
GX2461-1 | Glentham Life Sciences | 1 | EUR 1311.6 |
Antimony tin oxide (ATO); 99,95 % |
|||
GX2461-100 | Glentham Life Sciences | 100 | EUR 299.9 |
Antimony tin oxide (ATO); 99,95 % |
|||
GX2461-25 | Glentham Life Sciences | 25 | EUR 137.2 |
Antimony tin oxide (ATO); 99,95 % |
|||
GX2461-250 | Glentham Life Sciences | 250 | EUR 496.9 |
Antimony Powder -325 mesh, 99.5% |
|||
GX2647-100 | Glentham Life Sciences | 100 | EUR 107 |
Antimony Powder -325 mesh, 99.5% |
|||
GX2647-500 | Glentham Life Sciences | 500 | EUR 259.8 |
ICP Std Antimony 1000ug/mL in 1% HCl |
|||
PSB2A11 | Scientific Laboratory Supplies | 100ML | EUR 118.81 |
ICP Std Antimony 1000ug/mL in 10% HCl |
|||
PSB2A5 | Scientific Laboratory Supplies | 100ML | EUR 120.12 |
ICP Std Antimony 1000ug/mL in 20% HCl |
|||
PSB2B5 | Scientific Laboratory Supplies | 250ML | EUR 147.53 |
ICP Std Antimony 1000ug/mL in 10% HCl |
|||
PSB2C5 | Scientific Laboratory Supplies | 500ML | EUR 261.6 |
ICP Std Antimony 10000ug/mL in 10% HCl |
|||
PSB4A5 | Scientific Laboratory Supplies | 100ML | EUR 207.6 |
ICP Std Antimony 10000ug/mL in 20% HCl |
|||
PSB4B5 | Scientific Laboratory Supplies | 250ML | EUR 271.56 |
Antimony Shot 1-3 mm, 99.999% |
|||
GX5423-50 | Glentham Life Sciences | 50 | EUR 208.6 |
Antimony Shot 1-3 mm, 99.9999% |
|||
GX3665-10 | Glentham Life Sciences | 10 | EUR 110 |
Antimony Shot 1-3 mm, 99.9999% |
|||
GX3665-50 | Glentham Life Sciences | 50 | EUR 257.4 |
AAS Antimony Std 1000ppm in H2O |
|||
AASBH | Scientific Laboratory Supplies | 500ML | EUR 106.8 |
AAS Antimony Std 10000ppm in H2O |
|||
AASBM | Scientific Laboratory Supplies | 500ML | EUR 285.6 |
Antimony Rod 6 mm diameter, 99.999% |
|||
GX5626-50 | Glentham Life Sciences | 50 | EUR 505.1 |
Antimony Rod 8 mm diameter, 99.999% |
|||
GX9225-50 | Glentham Life Sciences | 50 | EUR 510 |
ICP Std Antimony 1000ug/mL in 6% Tart. Acid |
|||
PSB2B4 | Scientific Laboratory Supplies | 250ML | EUR 152.76 |
Antimony Powder max. 250 micron, 99.999% |
|||
GX3000-10 | Glentham Life Sciences | 10 | EUR 125.1 |
Antimony Powder max. 250 micron, 99.999% |
|||
GX3000-100 | Glentham Life Sciences | 100 | EUR 453 |
Antimony Powder max. 250 micron, 99.999% |
|||
GX3000-50 | Glentham Life Sciences | 50 | EUR 272.2 |
ICP Std Antimony 1000ug/mL in 1% HF + 5% HNO3 |
|||
PSB2C4 | Scientific Laboratory Supplies | 500ML | EUR 265.04 |
ICP Std Antimony 10000ug/mL in 1% HF + 5% HNO3 |
|||
PSB4A4 | Scientific Laboratory Supplies | 100ML | EUR 208.9 |
ICP Std Antimony 100ug/mL in 1% HF + 5% HNO3 |
|||
PSB1A4 | Scientific Laboratory Supplies | 100ML | EUR 212.4 |
ICP Std Antimony 10000ug/mL in 6% Tart. Acid tr. HNO3 |
|||
PSB4B4 | Scientific Laboratory Supplies | 250ML | EUR 236.31 |
ICP Standard Antimony Plus Tr HNO3 1000ug/ml |
|||
PSB2A4 | Scientific Laboratory Supplies | 100ML | EUR 120 |
Kinesis Hollow Cathode Lamp Antimony 37mm Std |
|||
CHR5943 | Scientific Laboratory Supplies | EACH | EUR 334.23 |
Lead, Antimony alloy, 2.5-3.5% Sb, shot 2-3 mm |
|||
GX9319-1 | Glentham Life Sciences | 1 | EUR 120.5 |
Lead, Antimony alloy, 2.5-3.5% Sb, shot 2-3 mm |
|||
GX9319-500 | Glentham Life Sciences | 500 | EUR 87.4 |
Kinesis Hollow Cathode Lamp Antimony 50mm Standard |
|||
CHR5951 | Scientific Laboratory Supplies | EACH | EUR 463.49 |
EP Reagent Conc to make Antimony Sb Sol. 1000ppm |
|||
5000400C | Scientific Laboratory Supplies | 100ML | EUR 217.2 |
Antimony 1000 ug/g (1000 PPM) for AA and ICP 50 grams in Base Oil 20 |
|||
ORG-SB8-2Z | Scientific Laboratory Supplies | 50G | EUR 79.2 |
Kinesis Hollow Cathode Lamp Antimony 37mm unicam Coded |
|||
CHR5947 | Scientific Laboratory Supplies | EACH | EUR 385.15 |
Kinesis Hollow Cathode Lamp Antimony 37mm Varian Coded |
|||
CHR5949 | Scientific Laboratory Supplies | EACH | EUR 385.15 |
Kinesis Hollow Cathode Lamp Antimony 50mm PE AAnalyst (Lumina) |
|||
CHR5953 | Scientific Laboratory Supplies | EACH | EUR 590.13 |
Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 500mL in 20% HCl |
|||
PLSB52X | Scientific Laboratory Supplies | 500ML | EUR 210 |
Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 30mL in H2O / 0.6% Tart. Acid / Tr. HNO3 |
|||
PLSB7-2M | Scientific Laboratory Supplies | 30ML | EUR 34.8 |
Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 250mL in H2O / 0.6% Tart. Acid / Tr. HNO3 |
|||
PLSB7-2T | Scientific Laboratory Supplies | 250ML | EUR 111.6 |
Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 500mL in H2O / 0.6% Tart. Acid / Tr. HNO3 |
|||
PLSB7-2X | Scientific Laboratory Supplies | 500ML | EUR 144 |
Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 125mL in H2O / 0.6% Tart. Acid / Tr. HNO3 |
|||
PLSB7-2Y01 | Scientific Laboratory Supplies | 125ML | EUR 63.6 |
Assurance Grade Antimony for AA and ICP 10000 ug/mL (10000 PPM) 500mL in H2O / 6% Tart. Acid / 1% HNO3 |
|||
PLSB7-3X | Scientific Laboratory Supplies | 500ML | EUR 255.6 |
Assurance Grade Antimony for AA and ICP 10000 ug/mL (10000 PPM) 125mL in H2O / 6% Tart. Acid / 1% HNO3 |
|||
PLSB7-3Y | Scientific Laboratory Supplies | 125ML | EUR 116.4 |
Claritas PPT Grade Antimony for ICP-MS 1000 ug/mL (1000 PPM) 30mL in H2O / 0.6% Tart. Acid / Tr. HNO3 |
|||
CLSB7-2M | Scientific Laboratory Supplies | 30ML | EUR 50.4 |
Claritas PPT Grade Antimony for ICP-MS 1000 ug/mL (1000 PPM) 125mL in H2O / 0.6% Tart. Acid / Tr. HNO3 |
|||
CLSB7-2Y | Scientific Laboratory Supplies | 125ML | EUR 110.4 |
Antimonyl (potassium tartrate trihydrate) |
|||
HY-B1082 | MedChemExpress | 100mg | EUR 142.8 |
Potassium antimonyl tartrate trihydrate, 99.5+% |
|||
GX0998-100 | Glentham Life Sciences | 100 | EUR 102.4 |
Potassium antimonyl tartrate trihydrate, 99.5+% |
|||
GX0998-500 | Glentham Life Sciences | 500 | EUR 233 |
Triton Extraction Buffer(TEB), for Histon Extraction |
|||
T8300-100 | GenDepot | 100ml | EUR 151.2 |
Triton Extraction Buffer(TEB), for Histon Extraction |
|||
T8300-500 | GenDepot | 500ml | EUR 170.4 |
anti-MON1B |
|||
YF-PA17649 | Abfrontier | 50 ug | EUR 435.6 |
Description: Mouse polyclonal to MON1B |
1,3,5‐TRIOXANE |
|||
920024 | Survival Technologies | each | Ask for price |
Anti-MON2 antibody |
|||
STJ118940 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-MON1B antibody |
|||
STJ119697 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-MON1A antibody |
|||
STJ119930 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Melanocortin Receptor 3 (extracellular) Antibody |
|||
A02841 | BosterBio | 200ul | EUR 793.2 |
Description: Rabbit Polyclonal Melanocortin Receptor 3 (extracellular) Antibody. Validated in IHC, WB and tested in Human, Mouse, Rat. |
Trioxsalen |
|||
C4451-100 | ApexBio | 100 mg | EUR 151.2 |
Description: Trioxsalen has been reported to intercalate into DNA forming DNA single-strand adducts and interstrand crosslinks when activated with UV light.In vitro: Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative. |
Trioxsalen |
|||
C4451-250 | ApexBio | 250 mg | EUR 278.4 |
Description: Trioxsalen has been reported to intercalate into DNA forming DNA single-strand adducts and interstrand crosslinks when activated with UV light.In vitro: Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative. |
Trioxsalen |
|||
C4451-500 | ApexBio | 500 mg | EUR 374.4 |
Description: Trioxsalen has been reported to intercalate into DNA forming DNA single-strand adducts and interstrand crosslinks when activated with UV light.In vitro: Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative. |
Trioxsalen |
|||
HY-B1157 | MedChemExpress | 500mg | EUR 308.4 |
Anti-MON1A (aa589-601) antibody |
|||
STJ72146 | St John's Laboratory | 100 µg | EUR 430.8 |
Anti-MON1A (aa478-489) antibody |
|||
STJ72147 | St John's Laboratory | 100 µg | EUR 430.8 |
2D Protein Extraction Buffer Trial Kit 1 x for 50mL |
|||
28943522 | Scientific Laboratory Supplies | EACH | EUR 204 |
Indium antimonide, 99.999% |
|||
GX8407-10 | Glentham Life Sciences | 10 | EUR 555.4 |
Indium antimonide, 99.999% |
|||
GX8407-2 | Glentham Life Sciences | 2 | EUR 179.3 |
Rabbit Anti-Monkey IgG(h+l) |
|||
C020217-100mg | Unibiotest | 100mg | EUR 3162 |
Rabbit Anti-Monkey IgG(h+l) |
|||
C020217-1mg | Unibiotest | 1mg | EUR 181.2 |
mAb mouse anti-monkey IL-4 |
|||
CT103 | U-CyTech | 0.5 mg | EUR 312 |
mAb mouse anti-monkey IL-6 |
|||
CT104 | U-CyTech | 0.5 mg | EUR 312 |
mAb mouse anti-monkey IL-5 |
|||
CT105 | U-CyTech | 0.5 mg | EUR 312 |
mAb mouse anti-monkey IL-2 |
|||
CT112 | U-CyTech | 0.5 mg | EUR 312 |
mAb mouse anti-monkey CD3 |
|||
CT161 | U-CyTech | 0.5 mg | EUR 457.2 |
Rabbit Anti-Monkey IgG |
|||
FNSA-0099 | FN Test | 500 uL | EUR 367.92 |
Description: Rabbit Anti-Monkey IgG secondary antibody |
Gallium antimonide, 99.99% |
|||
GX0988-2 | Glentham Life Sciences | 2 | EUR 198.7 |
5X Bacterial Protein Extraction Reagent (Tris) |
|||
AKR-180 | Cell Biolabs | 50mL | EUR 331.2 |
Description: The Cell Biolabs Bacterial Protein Extraction Reagents contain a gentle, nonionic detergent formulation which quickly extracts functional, recombinant protein from E. coli without mechanical disruption. |
Anti-monkey CD3 antibody |
|||
STJ15100146 | St John's Laboratory | 500 µl | EUR 210 |
Description: The anti-CD3 antibody is a useful tool for polyclonal activation of monkey T cells. Induction of cytokine secretion is dependent on number, nature and viability of accessory cells. |
mAb mouse anti-monkey IFN-γ |
|||
CT101 | U-CyTech | 0.5 mg | EUR 334.8 |
mAb mouse anti-monkey IL-10 |
|||
CT107 | U-CyTech | 0.5 mg | EUR 312 |
mAb mouse anti-monkey IL-13 |
|||
CT109 | U-CyTech | 0.5 mg | EUR 312 |
AR antibody |
|||
10R-2031 | Fitzgerald | 100 ul | EUR 483.6 |
Description: Mouse monoclonal AR antibody |
AR antibody |
|||
70R-35838 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Rabbit polyclonal AR antibody |
AR Antibody |
|||
ABD6783 | Lifescience Market | 100 ug | EUR 525.6 |
AR Antibody |
|||
32572-100ul | SAB | 100ul | EUR 302.4 |
AR Antibody |
|||
AF6137 | Affbiotech | 200ul | EUR 420 |
AR Antibody |
|||
AF6927 | Affbiotech | 100ul | EUR 420 |
AR Antibody |
|||
BF0349 | Affbiotech | 200ul | EUR 540 |
AR Antibody |
|||
BF0418 | Affbiotech | 200ul | EUR 540 |
AR Antibody |
|||
CSB-PA001975KA01HU- | Cusabio | each | EUR 402 |
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, ICC;WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100 |
AR Antibody |
|||
CSB-PA001975KA01HU-100ul | Cusabio | 100ul | EUR 466.8 |
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, ICC;WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100 |
AR Antibody |
|||
DF6783 | Affbiotech | 200ul | EUR 420 |
AR Antibody |
|||
1-CSB-PA011255 | Cusabio |
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000 |
AR Antibody |
|||
1-CSB-PA011256 | Cusabio |
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000 |
AR Antibody |
|||
1-CSB-PA011257 | Cusabio |
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, IF, ELISA;IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/40000 |
AR Antibody |
|||
1-CSB-PA011258 | Cusabio |
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
AR Antibody |
|||
1-CSB-PA006094 | Cusabio |
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/10000 |
AR Antibody |
|||
1-CSB-PA056943 | Cusabio |
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100 |
×
The proposed technique demonstrates the potential formation of environmentally related U(vi) colloidal nanoparticles showing notably attention-grabbing for the preparation of reference methods within the absence of added ions and capping brokers.
Tags: 3x flag tag dna sequence 3x flag tag sequence corticosterone elisa kit crispr cas9 vector cypridina ecori restriction enzyme geneart crispr gfp plasmid gfp sequence gibson assembly reaction gst protein sequence gst tag sequence invitrogen crispr cas9 kpni lenti 293t lenti blast lenti boost lenti cas9 lenti cells lenti depaul lenti gfp lenti guide lenti latin lenti luca lenti max lenti orf lenti rna lenti shrna lenti srl lenti susi lenti vase lenti vsvg lenti zoo pbsk vector pcdna map pcmv gfp peptide bond peptide yy pet 24 vector pgc 1 alpha antibody pgipz shrna plasmid plasmid mini prep plasmid prep kit protein g agarose ptopo vector map qpcr primers scrambled shrna strep tag sequence taq pol